Company
BioVie Inc
NASDAQ:BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival).
58 stories
Dow closes sharply lower as oil surge fuels inflation fears
4:15pm: Oil spike hits stocks US stocks closed sharply lower on Tuesday as surging oil prices revived inflation worries and pushed investors to reassess the...
BioVie advances Parkinson’s Phase 3 development program with FDA engagement
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson’s disease...
Archive
Nasdaq dragged down by Tesla, Apple as Bitcoin closes in on record high
The Nasdaq was down 0.4% at 16,207 points, the Dow Jones was 0.3% lower at 38,990 points and the S&P 500 was 0.1% lower at 5,130 points
BioVie aims to treat Parkinson’s and Alzheimer’s by focusing on inflammation
“BioVie is one of only a small handful of companies even considering inflammation as the primary target for reducing symptoms in those two diseases,” BioVie CEO Cuong Do said